Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women☆1


      The objective of this study was to evaluate the contraceptive efficacy and clinical performance of a Nestorone subdermal implant (NES) in the postpartum period. NES (n = 100) and Copper T intrauterine device (T-Cu; n = 100) acceptors initiated contraception at 8 weeks postpartum and were followed at monthly intervals during the first year and at 3-month intervals thereafter. Pregnancy rates, breastfeeding performance, infant growth, bleeding pattern, and side effects were assessed. Blood and milk NES concentration were measured.
      No pregnancy occurred in 2195 and 2145 woman-months of NES implant and T-Cu use, respectively. No effect of NES on lactation and infant growth and no serious adverse events were observed. Lactational amenorrhea was significantly longer in NES users (353 ± 20 days) than in T-Cu users (201 ± 11 days). More NES users (55.8%) experienced prolonged bleedings than did T-Cu users (36.2%). Concentrations of NES in breast milk ranged between 54–135 pmol/liter. The Nestorone implant is a highly effective contraceptive, safe for breastfed infants because the steroid is inactive by the oral route.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • World Health Organization
        Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. WHO/FRH/FPP, Geneva1996
        • International Planned Parenthood Federation
        Statement on breast feeding, fertility, and post-partum contraception. Statement by the International Medical Advisory Panel, 1989: 1-5 (November)
        • Noé G.
        • Salvatierra A.M.
        • Heikinheimo O.
        • Maturana X.
        • Croxatto H.B.
        Pharmacokinetics and bioavailability of ST-1435 administered by different routes.
        Contraception. 1993; 48: 548-556
        • Heikinheimo O.
        • Noé G.
        • Haukkamaa M.
        • Lähteenmäki P.
        The progestin ST-1435 rapid metabolism in man.
        Contraception. 1994; 50: 275-289
        • Coutinho E.M.
        • Da Silva A.R.
        • Carreira C.M.V.
        • Sivin I.
        Long-term contraception with a single implant of the progestin ST-1435.
        Fertil Steril. 1981; 36: 737-740
        • Lähteenmäki P.
        • Weiner E.
        • Lähteenmäki P.L.A.
        • Johansson E.
        • Luukainen T.
        Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435.
        Contraception. 1981; 23: 63-75
        • Haukkamaa M.
        • Laurikka-Routti M.
        • Heikinheimo O.
        • Moo-Young A.
        Contraception with subdermal implants releasing the progestin ST-1435.
        Contraception. 1992; 45: 49-55
        • Dı́az S.
        • Schiappacasse V.
        • Pavez M.
        • et al.
        Clinical trial with Nestorone™ subdermal contraceptive implant.
        Contraception. 1995; 51: 33-38
        • Lähteenmäki P.L.A.
        Contraceptive action of a synthetic progestin, ST-1435 (academic dissertation). Steroid Research Laboratory, Department of Medical Chemistry, University of Helsinki, Helsinki, Finland1986
        • Lähteenmäki P.
        • Weiner E.
        • Lähteenmäki P.
        • Johansson E.D.B.
        • Luukkainen T.
        Pituitary, and ovarian function during contraception with one s.c. implant releasing a progestin, ST-1435.
        Contraception. 1982; 25: 299-306
        • Lähteenmäki P.L.A.
        • Lähteenmäki P.
        Contraception-dependent mechanisms of ovulation inhibition by the progestin ST-1435.
        Fertil Steril. 1985; 44: 19-24
        • Brache V.
        • Massai R.
        • Mishell Jr, D.R.
        • et al.
        Ovarian function during use of Nestorone® subdermal implants.
        Contraception. 2000; 61: 199-204
        • Odlind V.
        • Lithell H.
        • Selenius J.
        • Vessby B.
        Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435.
        Contraception. 1985; 31: 123-130
        • Lähteenmäki P.L.A.
        • Dı́az S.
        • Miranda P.
        • Croxatto H.
        • Lähteenmäki P.
        Milk, and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435.
        Contraception. 1990; 43: 555-562
      1. Nelson W.E. Textbook of Pediatrics. 8th ed. WB Saunders Company, Philadelphia1964
        • SAS/STAT Software
        The PHREG procedure, preliminary documentation. SAS Institute Inc, Cary, NC1991
        • Fleiss J.L.
        Statistical methods for rates, and proportions. John Wiley & Sons, New York1981: 24-36
        • Pinol A.
        • Machin D.
        A microcomputer software for analysis of menstrual diaries.
        Contraception. 1988; 38: 157-163
        • Hollander M.
        • Wolfe D.
        Nonparametric statistical methods. John Wiley & Sons, New York1972: 115,125, 131
        • SAS Institute Inc
        SAS/STAT™ guide for personal computers. 6th ed. SAS Institute Inc, Cary, NC1987
        • WHO Task Force for Epidemiological Research on Reproductive Health, Special Programme of Research, Development, and Research Training in Human Reproduction
        Progestogen-only contraceptives during lactation.
        Contraception. 1994; 50: 35-53
        • Dı́az S.
        • Zepeda A.
        • Maturana X.
        • et al.
        Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, NorplantR implants, and Copper T 380-A intrauterine devices.
        Contraception. 1997; 56: 223-232
        • Croxatto H.B.
        • Dı́az S.
        • Peralta O.
        • et al.
        Fertility regulation in nursing women. IV. Long-term influence of a low-dose combined oral contraceptive initiated at day 30 postpartum upon lactation and infant growth.
        Contraception. 1983; 27: 13-25
        • World Health Organization
        Effects of hormonal contraceptives on breast milk composition and infant growth.
        Stud Fam Plann. 1988; 6: 361-369
        • Sivin I.
        • Dı́az S.
        • Croxatto H.B.
        • et al.
        Contraceptives for lactating women.
        Contraception. 1997; 55: 225-232
        • Harlap S.
        Exposure to contraceptive hormones through breast milk—are there long-term health and behavioral consequences?.
        Int J Gynaecol Obstet. 1987; 25: 47-55
        • Coutinho E.
        • Athayde C.
        • Dantas C.
        • Hirsh C.
        • Barbosa I.
        Use of a single implant of Elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women.
        Contraception. 1999; 59: 115-122
        • Croxatto H.B.
        • Dı́az S.
        The place of progesterone in human contraception.
        J Steroid Biochem. 1987; 27: 991-994
        • Koetsawang S.
        • Nukulkarn P.
        • Fotherby K.
        • Shrimanker K.
        • Mangalam M.
        • Towobola K.
        Transfer of contraceptive steroids in milk of women using long-acting gestagens.
        Contraception. 1982; 25: 321-331
        • Chi I.-Ch.
        • Potts M.
        • Wilkens L.R.
        • Champion Ch.B.
        Performance of the Copper T-380 A intrauterine device in breastfeeding women.
        Contraception. 1989; 39: 603-618